UNASSIGNED: Allogeneic stem cell transplantation (allo-SCT) outcomes in @entity1 with @entity978 ( @entity978 ) remain poorly defined. We performed a meta-analysis of allo-SCT studies in @entity978 @entity1 . The primary endpoints were 6-month, 1-year, 2-year and 3-year relapse-free survival (RFS) and @entity1349 ( @entity1349 ). A total of 42 reports (1850 @entity1 ) was included. The pooled estimates (95% confidence interval) for 6-month, 1-year, 2-year and 3-year RFS were 77 (59-91)%, 50 (42-57)%, 37 (31-43)% and 31 (25-37)%, respectively. The corresponding numbers for @entity1349 were 83 (75-91)%, 68 (62-74)%, 58 (52-64)% and 50 (41-58)%, respectively. There was statistical heterogeneity among studies in all outcomes. In meta-regression, accrual initiation year in 2000 or later was associated with higher 6-month (P=0.012) and 1-year @entity1349 (P=0.046), and pre-SCT remission with higher 2-year @entity1349 (P=0.047) and 1-year RFS (P=0.016). In conclusion, outcomes of allo-SCT in @entity978 have improved over time, with 5-10% lower non-relapse mortality and relapse rates, and 15-20% higher RFS and @entity1349 in studies that initiated accrual in 2000 or later compared with earlier studies. However, there is no apparent survival plateau, demonstrating the need to improve on current allo-SCT strategies in relapsed/refractory @entity978 .Bone Marrow Transplantation advance online publication, 4 January 2016; doi:10.1038/bmt.2015.332.

Allogeneic hematopoietic stem cell transplantation in XXXX : a systematic review and meta-analysis.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity978 :: ('MESH:D006689', 'Disease') :: ['HL', 'Hodgkin lymphoma'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity978 :: (MESH:D006689,Disease) :: ['Hodgkin lymphoma']
